CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
我如何检测双特异性单克隆抗体和 19CAR-T 细胞治疗后的 B 细胞前体急性淋巴细胞白血病可测量残留病
英文原题：How I Investigate Measurable Residual Disease in B-Cell Precursor Acute Lymphoblastic Leukemia After Therapy With Bi-Specific Monoclonal Antibodies and 19CAR-T Cells.
查看英文原题
How I Investigate Measurable Residual Disease in B-Cell Precursor Acute Lymphoblastic Leukemia After Therapy With Bi-Specific Monoclonal Antibodies and 19CAR-T Cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
在 CD19 靶向治疗后，需要采用不同的策略来检测 MRD，而不依赖 CD19 进行 B 细胞群设门。然而，必须根据可用资源使用经过验证的方案，以确保为临床决策提供可靠的结果。
研究思路结论见上方概要
背景
在抗CD19靶向治疗后，B细胞前体急性淋巴细胞白血病（BCP-ALL）的可测量残留病（MRD）需要特定策略来识别残留原始细胞，因为CD19表达缺失或降低使其作为B细胞设门的原始标志物不一致。
目的
由于BCP-ALL患者越来越多地能够获得CD3/CD19双特异性T细胞衔接器（BiTe）和靶向CD19的CAR-T 细胞治疗，流式细胞术实验室必须做好准备以评估治疗反应。
方法
在此描述了在抗CD19治疗背景下经过验证的MRD检测策略，可根据不同流式细胞术实验室的设施条件加以采用。本文包括一种基于替代设门、无需使用额外标志物的8色流式细胞术（FC）策略用于BCP-ALL MRD检测（Euroflow方案），以及使用CD19替代标志物的其他策略，包括2种使用8色的方案、1种使用10色的方案和另1种使用14色/15标志物的方案。
展开英文摘要原文
OBJECTIVE
Due to the increased access of BCP-ALL patients to therapies with CD3/CD19 bispecific T-cell engagers (BiTe) and CD19-targeted chimeric antigen receptor T-Cell (CAR-T), it is essential that flow cytometry laboratories are prepared to evaluate therapeutic responses. MATERIAL AND METHODS: Here, validated strategies for MRD detection in the context of anti-CD19 therapies are described, accessible to flow cytometry laboratories according to their different facilities. The paper includes an 8-color flow cytometry (FC) strategy for BCP-ALL MRD based on alternative gating without the use of additional markers (Euroflow protocol), as well as other strategies using alternative markers to CD19, comprising 2 protocols using 8 colors, one using 10 colors and another 14 colors/15 markers.
CONCLUSION
Different strategies are needed to detect MRD without using CD19 for B-cell population gating after CD19-targeted therapies. However, it is essential that validated protocols are used according to the available resources to ensure reliable results for clinical decision-making.
论文信息
- 作者
- Valerio Ikoma-Colturato MR、Furtado FM、de Oliveira E、Gevert F、Mendonça R、Brazilian Society of Bone Marrow and Cell Therapy (SBTMO) MRD Working Group
- 第一作者单位
- Hospital Amaral Carvalho, Jaú, Brazil.Brazil
- 通讯作者单位
- Hospital da Criança de Brasília José Alencar, Brasília, Brazil.Brazil
- 文献类型
- 综述
- 期刊
- International journal of laboratory hematology2025 Jun
- 原文标识
- PubMed 40007453 · DOI 10.1111/ijlh.14448